BMS Plans 265 Princeton Layoffs – Bristol Myers Squibb Extends Its USD 2 Billion Cost Cutting Drive
Company

BMS Plans 265 Princeton Layoffs – Bristol-Myers Squibb Extends Its USD 2 Billion Cost Cutting Drive

Tangzhi Pharma Secures Nearly RMB 100 Million Exclusive Financing from Fengnian Capital – Glyco Raw‑Material Platform Targets ADC and Nucleic‑Acid Drug Boom
CompanyDeals

Tangzhi Pharma Secures Nearly RMB 100 Million Exclusive Financing from Fengnian Capital – Glyco Raw‑Material Platform Targets ADC and Nucleic‑Acid Drug Boom

Allist Pharmaceuticals' NDA Accepted by China's CDE for Furmonertinib in Adjuvant NSCLC – Third‑Generation EGFR‑TKI Targets Post‑Resection Patients with Exon 19 Deletion or L858R Mutations
CompanyDrug

Allist Pharmaceuticals’ NDA Accepted by China’s CDE for Furmonertinib in Adjuvant NSCLC – Third‑Generation EGFR‑TKI Targets Post‑Resection Patients with Exon 19 Deletion or L858R Mutations

BoomRay Licenses Preclinical Radioligand Therapy to Novartis in Exclusive Global Deal Worth Up to USD 900 Million – China RDC Specialist Adds Big Pharma Validation
CompanyDeals

BoomRay Licenses Preclinical Radioligand Therapy to Novartis in Exclusive Global Deal Worth Up to USD 900 Million – China RDC Specialist Adds Big Pharma Validation

Merck's Subcutaneous Pembrolizumab KEYJECT Wins MHLW Approval Across All KEYTRUDA Indications in Japan – Phase III Shows Comparable Exposure and 45% ORR in First-Line Metastatic NSCLC
CompanyDrug

Merck’s Subcutaneous Pembrolizumab KEYJECT Wins MHLW Approval Across All KEYTRUDA Indications in Japan – Phase III Shows Comparable Exposure and 45% ORR in First-Line Metastatic NSCLC

Roche's Susvimo Wins European Commission Approval for nAMD – Refillable Ranibizumab Implant Delivers Vision Outcomes Equivalent to Monthly Injections with Just Two Refills Per Year
CompanyDrug

Roche’s Susvimo Wins European Commission Approval for nAMD – Refillable Ranibizumab Implant Delivers Vision Outcomes Equivalent to Monthly Injections with Just Two Refills Per Year

Grünenthal to Acquire Bayer's Stivarga (Regorafenib) for Up to €375 Million – Oral Multikinase Oncology Franchise Changes Hands Ahead of 2029–2030 Loss of Exclusivity
Others

Grünenthal to Acquire Bayer’s Stivarga (Regorafenib) for Up to €375 Million – Oral Multikinase Oncology Franchise Changes Hands Ahead of 2029–2030 Loss of Exclusivity

Shanghai Shenqi Medical Partners with Bio-heart to Commercialize BioHeart Bioresorbable Sirolimus‑Eluting Coronary Stent – Ultra‑Thin 90μm Strut Design Targets Deliverability and Radial Strength
CompanyDeals

Shanghai Shenqi Medical Partners with Bio-heart to Commercialize BioHeart Bioresorbable Sirolimus‑Eluting Coronary Stent – Ultra‑Thin 90μm Strut Design Targets Deliverability and Radial Strength

HanX Biopharmaceuticals Signs Long‑Term Strategic Cooperation and AI Platform License with XtalPi Science – AI for Science to Power Antibody Design and Innovative Molecule Discovery
CompanyDeals

HanX Biopharmaceuticals Signs Long‑Term Strategic Cooperation and AI Platform License with XtalPi Science – AI for Science to Power Antibody Design and Innovative Molecule Discovery

AbbVie Taps Iambic's AI Platform in Multi-Year Collaboration – Enchant v3 Multimodal Model Targets First-in-Class Small Molecules in Immunology, Neuroscience and Oncology
CompanyDeals

AbbVie Taps Iambic’s AI Platform in Multi-Year Collaboration – Enchant v3 Multimodal Model Targets First-in-Class Small Molecules in Immunology, Neuroscience and Oncology

Jiangsu Hengrui Wins Dual NMPA Clinical Trial Approvals – SHR‑4595 Enters Advanced Solid Tumor Testing as HRS‑4729 Triple Agonist Advances to Phase II in CKD
CompanyDrug

Jiangsu Hengrui Wins Dual NMPA Clinical Trial Approvals – SHR‑4595 Enters Advanced Solid Tumor Testing as HRS‑4729 Triple Agonist Advances to Phase II in CKD

Yifan Pharmaceutical Secures China Rights to Boryung's Taxotere – Docetaxel Injection Commercialization Deal Covers Promotion, Distribution and Market Operations
CompanyDeals

Yifan Pharmaceutical Secures China Rights to Boryung’s Taxotere – Docetaxel Injection Commercialization Deal Covers Promotion, Distribution and Market Operations